The ACHIEVE-5 trial (ClinicalTrials.gov identifier: NCT06109311) was a randomized, double-blind, placebo-controlled study that included 546 T2D patients with inadequate glycemic control on insulin ...

Eli Lilly’s oral GLP-1 therapy, orforglipron, met all primary and key secondary endpoints in the Phase III ACHIEVE-2 and ACHIEVE-5 studies, showing significant A1C reduction, weight loss, and ...

Eli Lilly and Company's strong Phase 3 diabetes drug results boost its GLP-1 franchise. Click for my updated look at LLY ...

After beating Novo Nordisk’s semaglutide last month, Lilly’s much anticipated oral candidate orforglipron has taken down AstraZeneca’s Farxiga in a head-to-head trial.

Key Takeaways A new ICD-10 diagnosis code, E11.A, now formally recognizes type 2 diabetes in remissionRemission requires an ...

Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking ...

Authors say in those without diabetes, continuous glucose monitors are not a substitute for HbA1c. (HealthDay News) — Continuous glucose monitors (CGMs) do not accurately reflect blood sugar control ...

Eli Lilly (LLY) stock is in focus as the company's oral weight loss candidate orforglipron succeeds in two Phase 3 trials for ...

Type 1 diabetes wears many faces—an elusive autoimmune disease, a metabolic mess, a chronic condition that requires lifelong ...

Doctors and life-science companies are looking for alternative approaches to the treatment of type 1 diabetes (T1D) ...